Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Lowers Q1 2009 Guidance

NEW YORK (GenomeWeb News) – Agilent Technologies disclosed in a US Securities and Commission filing today that it has lowered its revenue and earnings-per-share guidance for its fiscal first quarter of 2009, which ends Jan. 31, 2009.
 
The firm said that due to “deteriorating economic conditions, particularly in electronic measurement markets,” it was lowering its revenue guidance to a range of between $1.25 billion and $1.3 billion. Last month, Agilent had predicted revenue of between $1.34 billion and $1.39 billion for the first quarter.
 
At that time, Agilent President and CEO Bill Sullivan said that the firm’s forecast for fiscal 2009 "is based on the assumption that an economic downturn in much of the world will continue through mid-2009, and that no geographies or markets will be entirely immune from its impact."
 
The company also lowered its EPS guidance for Q1 to a range of between $.28 and $.32, down from previous guidance of $.34 to $.38.
 
Agilent noted that the EPS guidance is non-GAAP and “excludes primarily the impacts of future restructuring and asset impairment charges and non-cash intangibles amortization.”
 
For the first quarter of 2008, Agilent brought in revenues of $1.39 billion and reported earnings per share of $.31.
 
 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.